doi: 10.1016/j.ajic.2007.01.012.
Fluoroquinolone resistance in pediatric bloodstream infections because of Escherichia coli and Klebsiella species
Affiliations
- PMID: 18241740
- DOI: 10.1016/j.ajic.2007.01.012
Item in Clipboard
Fluoroquinolone resistance in pediatric bloodstream infections because of Escherichia coli and Klebsiella species
Am J Infect Control.
2008 Feb.
Abstract
In pediatric bloodstream infections with fluoroquinolone (FQ)-resistant Escherichia coli and Klebsielia species, we noted an association between FQ resistance and extended-spectrum beta-lactamase (ESBL) production (OR, 12; 95% CI: 2.28-83.8). A case control study revealed no significant risk factors (including prior antibiotic use) for FQ resistance among ESBL E coli and Klebsiella species (ESBL-EK).
Similar articles
-
Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.Microb Drug Resist. 2012 Oct;18(5):518-24. doi: 10.1089/mdr.2012.0067. Epub 2012 Jun 28. Microb Drug Resist. 2012. PMID: 22742454
-
Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance.Braz J Infect Dis. 2009 Dec;13(6):403-7. doi: 10.1590/s1413-86702009000600003. Braz J Infect Dis. 2009. PMID: 20464329
-
Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.Pediatrics. 2005 Apr;115(4):942-9. doi: 10.1542/peds.2004-1289. Pediatrics. 2005. PMID: 15805368
-
Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.Clin Infect Dis. 2001 Oct 15;33(8):1288-94. doi: 10.1086/322667. Epub 2001 Sep 14. Clin Infect Dis. 2001. PMID: 11565067
-
Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.J Antimicrob Chemother. 2009 Mar;63(3):568-74. doi: 10.1093/jac/dkn514. Epub 2009 Jan 6. J Antimicrob Chemother. 2009. PMID: 19126669
Cited by
-
Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenic Escherichia coli ST1193 in Vietnam.Microb Genom. 2021 Dec;7(12):000733. doi: 10.1099/mgen.0.000733. Microb Genom. 2021. PMID: 34904942 Free PMC article.
-
Safety Concerns Surrounding Quinolone Use in Children.J Clin Pharmacol. 2016 Sep;56(9):1060-75. doi: 10.1002/jcph.715. Epub 2016 Mar 28. J Clin Pharmacol. 2016. PMID: 26865283 Free PMC article. Review.
-
Global fluoroquinolone resistance epidemiology and implictions for clinical use.Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14. Interdiscip Perspect Infect Dis. 2012. PMID: 23097666 Free PMC article.
-
Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Infection. 2012 Jun;40(3):239-62. doi: 10.1007/s15010-012-0257-2. Epub 2012 Mar 30. Infection. 2012. PMID: 22460782 Review.
-
Resistance against broad-spectrum beta-lactams among uropathogens in children.Pediatr Nephrol. 2009 Dec;24(12):2381-6. doi: 10.1007/s00467-009-1255-1. Epub 2009 Jul 28. Pediatr Nephrol. 2009. PMID: 19636594
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
